ArticleDiscover nano2026
The ginger-derived nanovesicles-coated albumin nanoparticles induce cell death and epigenetic regulation to treat colorectal cancer.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDue to the limitations of conventional cancer chemotherapy, including low bioavailability, limited indicators of therapeutic improvement, and unclear side effects, numerous laboratories have been actively engaged in the development of drug delivery systems. Here, we designed and synthesized a plant-derived ginger exosome-coated albumin nanoparticle drug delivery system (GEBSS) loaded with Shikonin (SHK) and STM2457 (a METTL3 inhibitor) and probes into the mechanism of antitumor.
methodsWe prepared and characterized GEBSS nanoparticles and evaluated their in vitro cellular uptake and targeting capabilities. The in vitro antitumor efficacy was assessed by measuring cell viability, clonogenic formation, oxidative stress, mitochondrial function, and apoptosis markers; biosafety was confirmed via a hemolysis assay. Furthermore, the ability of GEBSS to induce ICD was validated through Western blotting, ATP detection, and immunofluorescence assays, while its role in epigenetic regulation was elucidated using Dot Blot, MeRIP-qPCR, and RNA stability experiments. Finally, the in vivo antitumor effect of GEBSS was verified by intravenous administration in a nude mouse subcutaneous tumor model.
resultsA subsequent characterization revealed that GEBSS exhibited a concentrated size distribution around 142 nm, were efficiently absorbed by colorectal cancer (CRC) cells, and demonstrated inhibitory effects on tumor cell proliferation. In vivo experiments demonstrated excellent tumor-targeting ability, anti-tumor efficacy, and biocompatibility of GEBSS. Mechanistically, GEBSS induced apoptosis and immunogenic cell death (ICD) in tumor cells. Moreover, at the epigenetic regulation level, GEBSS suppressed cell proliferation by reducing the m6A methylation levels of immune checkpoint genes PD-L1 and CD47.
conclusionThis study explored the feasibility of producing naturally derived nanocarriers and, for the first time, employed a combination of SHK and STM2457 for CRC treatment, offering novel strategies and insights for nanomedicine in CRC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.